Yale Cancer Center member Sidi Chen, assistant professor of Genetics at Yale School of Medicine, and a member of the Yale West Campus Systems Biology Institute, was awarded a $500,000 research grant from Alliance for Cancer Gene Therapy to advance multiplexed activation of endogenous genes as an Immunotherapy or MAEGI technology.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
